Show simple item record

dc.contributor.authorAbu-Jaish, Alaa
dc.contributor.authorMecca, Gennaro
dc.contributor.authorJumaa, Salma
dc.contributor.authorThawabteh, Ameen
dc.date.accessioned2018-09-17T09:28:38Z
dc.date.available2018-09-17T09:28:38Z
dc.date.issued2015-06-05
dc.identifier.issn2277– 7105
dc.identifier.urihttps://dspace.alquds.edu/handle/20.500.12213/933
dc.description.abstractprodrugs are bioreversible derivatives of drug molecules that undergo intermolecular or intramolecular reactions by enzymatic or chemical biotransformation in the human body to give the corresponding active parent drugs and a non-toxic promoiety. Prodrugs have been extensively and successfully used as a chemical tool for modification of the physicochemical, pharmacokinetic as well as pharmacodynamic characteristics of commonly used drugs and new drugs.This mini review focuses on the design, synthesis and pharmacological effects of several prodrugs and codrugs of the non-steroidal anti-inflammatory (NSAIDs), mefenamic acid. Exploitation of the prodrug approach has the potential to achieve a reduction of mefenamic acid GI (gastrointestinal) intolerance, enhance its bioavailability, mask its unpleasant sensation and prolong its duration of action. In addition, utilizing the prodrug concept migh enhance the bioavailability of the counter partner drug of mefenamic acid codrug by increasing its lipophilicity.en_US
dc.language.isoen_USen_US
dc.publisherWJPR,Tara Pal,WJPRen_US
dc.subjectAnti-inflammatory drugsen_US
dc.subjectMefenamic acid prodrugsen_US
dc.subjectMefenamic acid codrugsen_US
dc.subjectProdrugs chemical approachen_US
dc.subjectNSAIDs drugsen_US
dc.subjectProdrugs catalyzed by enzymesen_US
dc.titleMefenamic acid prodrugs and codrugs - two decades of developmenten_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record